Home > Education & Research > Research to Improve Health Care > Participating in Research > Clinical Trials > Clinical Trials Details
<< Back to Results
This randomized phase III trial studies lenalidomide to see how well it works with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia. Lenalidomide may stop the growth of myelodysplastic syndrome by blocking blood flow to the cells. Colony stimulating factors, such as epoetin alfa, may increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known whether lenalidomide is more effective with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia.
Essentia Health Duluth
For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.